Research ExplorerPublicationsTransfer of autologous gene-modified T cells in HIV-infected...

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Standard

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. / van Lunzen, Jan; Glaunsinger, Tobias; Stahmer, Ingrid; von Baehr, Volker; Baum, Christopher; Schilz, Andrea; Kuehlcke, Klaus; Naundorf, Sonja; Martinius, Holger; Hermann, Felix; Giroglou, Tsanan; Newrzela, Sebastian; Müller, Ingrid; Brauer, Francis; Brandenburg, Gunda; Alexandrov, Alexander; von Laer, Dorothee.

In: MOL THER, Vol. 15, No. 5, 5, 2007, p. 1024-1033.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

van Lunzen, J, Glaunsinger, T, Stahmer, I, von Baehr, V, Baum, C, Schilz, A, Kuehlcke, K, Naundorf, S, Martinius, H, Hermann, F, Giroglou, T, Newrzela, S, Müller, I, Brauer, F, Brandenburg, G, Alexandrov, A & von Laer, D 2007, 'Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.', MOL THER, vol. 15, no. 5, 5, pp. 1024-1033. <http://www.ncbi.nlm.nih.gov/pubmed/17356541?dopt=Citation>

APA

van Lunzen, J., Glaunsinger, T., Stahmer, I., von Baehr, V., Baum, C., Schilz, A., Kuehlcke, K., Naundorf, S., Martinius, H., Hermann, F., Giroglou, T., Newrzela, S., Müller, I., Brauer, F., Brandenburg, G., Alexandrov, A., & von Laer, D. (2007). Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. MOL THER, 15(5), 1024-1033. [5]. http://www.ncbi.nlm.nih.gov/pubmed/17356541?dopt=Citation

Vancouver

van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. MOL THER. 2007;15(5):1024-1033. 5.

Bibtex

@article{32a54e31e0f7418d9ae5053853b1f755,
title = "Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.",
abstract = "Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. We tested the infusion of T lymphocytes transduced with a retroviral vector (M87o) that expresses an HIV entry-inhibitory peptide (maC46). Gene-modified autologous T cells were infused into ten HIV-infected patients with advanced disease and multidrug-resistant virus during anti-retroviral combination therapy. T-cell infusions were tolerated well, with no severe side effects. A significant increase of CD4 counts was observed after infusion. At the end of the 1-year follow-up, the CD4 counts of all patients were still around or above baseline. Gene-modified cells could be detected in peripheral blood, lymph nodes, and bone marrow throughout the 1-year follow-up, and marking levels correlated with the cell dose. No significant changes of viral load were observed during the first 4 months. Four of the seven patients who changed their antiviral drug regimen thereafter responded with a significant decline in plasma viral load. In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.",
author = "{van Lunzen}, Jan and Tobias Glaunsinger and Ingrid Stahmer and {von Baehr}, Volker and Christopher Baum and Andrea Schilz and Klaus Kuehlcke and Sonja Naundorf and Holger Martinius and Felix Hermann and Tsanan Giroglou and Sebastian Newrzela and Ingrid M{\"u}ller and Francis Brauer and Gunda Brandenburg and Alexander Alexandrov and {von Laer}, Dorothee",
year = "2007",
language = "Deutsch",
volume = "15",
pages = "1024--1033",
journal = "MOL THER",
issn = "1525-0016",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

AU - van Lunzen, Jan

AU - Glaunsinger, Tobias

AU - Stahmer, Ingrid

AU - von Baehr, Volker

AU - Baum, Christopher

AU - Schilz, Andrea

AU - Kuehlcke, Klaus

AU - Naundorf, Sonja

AU - Martinius, Holger

AU - Hermann, Felix

AU - Giroglou, Tsanan

AU - Newrzela, Sebastian

AU - Müller, Ingrid

AU - Brauer, Francis

AU - Brandenburg, Gunda

AU - Alexandrov, Alexander

AU - von Laer, Dorothee

PY - 2007

Y1 - 2007

N2 - Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. We tested the infusion of T lymphocytes transduced with a retroviral vector (M87o) that expresses an HIV entry-inhibitory peptide (maC46). Gene-modified autologous T cells were infused into ten HIV-infected patients with advanced disease and multidrug-resistant virus during anti-retroviral combination therapy. T-cell infusions were tolerated well, with no severe side effects. A significant increase of CD4 counts was observed after infusion. At the end of the 1-year follow-up, the CD4 counts of all patients were still around or above baseline. Gene-modified cells could be detected in peripheral blood, lymph nodes, and bone marrow throughout the 1-year follow-up, and marking levels correlated with the cell dose. No significant changes of viral load were observed during the first 4 months. Four of the seven patients who changed their antiviral drug regimen thereafter responded with a significant decline in plasma viral load. In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.

AB - Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. We tested the infusion of T lymphocytes transduced with a retroviral vector (M87o) that expresses an HIV entry-inhibitory peptide (maC46). Gene-modified autologous T cells were infused into ten HIV-infected patients with advanced disease and multidrug-resistant virus during anti-retroviral combination therapy. T-cell infusions were tolerated well, with no severe side effects. A significant increase of CD4 counts was observed after infusion. At the end of the 1-year follow-up, the CD4 counts of all patients were still around or above baseline. Gene-modified cells could be detected in peripheral blood, lymph nodes, and bone marrow throughout the 1-year follow-up, and marking levels correlated with the cell dose. No significant changes of viral load were observed during the first 4 months. Four of the seven patients who changed their antiviral drug regimen thereafter responded with a significant decline in plasma viral load. In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.

M3 - SCORING: Zeitschriftenaufsatz

VL - 15

SP - 1024

EP - 1033

JO - MOL THER

JF - MOL THER

SN - 1525-0016

IS - 5

M1 - 5

ER -